Skip to main content

Table 4 Summary of detailed clinical data and immunohistochemistry results (n = 18)

From: Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma

Gender

Age

Intensity of phosphorylated targets

PFS (months)

Response

AKT

mTOR

S6RP

4EBP1

F

47

3

2

2

2

1.6

PD

M

52

0

2

1

1

11.9

SD ≥ 6 m

M

46

1

1

1

2

15.8+

SD ≥ 6 m

M

20

2

0

1

2

3.7

SD < 6 m

M

48

0

1

1

3

8.4

SD ≥ 6 m

F

50

0

1

0

0

3.8

SD < 6 m

M

51

3

3

1

3

8.6

SD ≥ 6 m

M

59

2

2

2

3

14.1

SD ≥ 6 m

M

63

1

2

1

1

14.0

SD ≥ 6 m

M

42

2

1

3

1

5.6

SD < 6 m

M

47

1

0

0

2

1.7

PD

M

49

2

0

2

1

5.5

SD < 6 m

M

59

2

0

0

0

3.7

SD < 6 m

F

57

0

2

1

3

12.0+*

SD ≥ 6 m

M

57

0

2

2

2

4.7

SD < 6 m

M

42

0

2

3

0

11.3

SD ≥ 6 m

F

51

0

3

1

2

14.4+*

SD ≥ 6 m

M

64

3

3

3

3

12.3+*

PR

  1. Abbreviations: CR complete response, F female, M male, m months, PD progression of disease, PFS progression-free survival, PR partial response, SD stable disease.
  2. *The symbol “+” represents the patients who did not experience progression of disease by the cut-off date.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us